| Today’s Big NewsMar 15, 2024 |
|
March 18-20, 2024 | Savannah, GA
The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer.
Secure 50% off Your Fierce TMF Summit Pass | LIMITED Passes Available: Use Promo Code LASTCHANCE.
Secure your spot Today!
|
|
| By Max Bayer Moderna does not plan to advance a midstage Zika vaccine without additional outside cash, despite receiving US funding thus far, according to a regulatory disclosure. |
|
|
|
By Annalee Armstrong Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis drug has been approved, to be sold as Rezdiffra. For the other companies with up-and-coming treatments in the clinic, the question is: What now? |
By Max Bayer Biogen CMO Maha Radhakrishnan has departed the company, a spokesperson confirmed. It was her second stint at the company after she rejoined in 2020. |
By Nick Paul Taylor Geron has triumphed in its latest uphill battle. Facing questions about the trade-offs of its blood cancer drug candidate imetelstat, the biotech won over an FDA advisory committee and secured a 12 to 2 vote in its favor—triggering a surge in its share price. |
|
Protect performance with a high-purity RNase Inhibitor that preserves RNA at elevated temperatures. Maintain accurate transcript abundance with a high-efficiency, low-bias cDNA amplification polymerase.
|
|
By James Waldron During Big Pharma’s flurry of antibody-drug conjugate (ADC) deals late last year, China emerged as the go-to location to source the tech for this red-hot modality. Now, two Chinese biotechs have paired up again for their own ADC exercise. |
By Max Bayer,Gabrielle Masson Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research unit. Rigel hires CMO vet for same role. |
By Ayla Ellison,Annalee Armstrong In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
By Angus Liu The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended. The FDA has approved Madrigal's resmetirom under the brand name Rezdiffra as the first drug for the fatty liver disease. |
By Conor Hale Better Therapeutics had previously laid off a third of its workers and instituted company-wide pay cuts as it sought reimbursements and revenue for its AspyreRx cognitive behavioral therapy app for Type 2 diabetes. |
By Andrea Park As GLP-1 drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy have spent the last couple of years skyrocketing in popularity—with no signs of slowing down—it was perhaps only a matter of time before they further shook up the pharma industry. |
By Conor Hale The latest issue of the New England Journal of Medicine featured a duet of expansive studies from Guardant Health and Exact Sciences, examining their upcoming tests that aim to increase screening rates and catch earlier cases of colorectal cancer. |
By Angus Liu WuXi AppTec left BIO amid alleged biosecurity concerns and as U.S. lawmakers target certain Chinese biotechs. Takeda will shut down a gene therapy manufacturing and R&D facility in Austria. The FDA questioned whether Carvykti should be approved in an earlier line of multiple myeloma after noticing an early detriment to patient survival in a clinical trial. And more. |
By Dave Muoio The Bay State's healthcare cost growth benchmark program is calling for policy action after a report showed per-person health spending well above the national average. |
Fierce podcastsDon’t miss an episode |
| | In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
